{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T16:57:33Z","timestamp":1790269053111,"version":"4.1.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Czech Republic - conceptual development of research organisation","award":["65269705"],"award-info":[{"award-number":["65269705"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejog.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.ejogrb.2018.06.036","type":"journal-article","created":{"date-parts":[[2018,6,20]],"date-time":"2018-06-20T22:27:27Z","timestamp":1529533647000},"page":"154-160","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer"],"prefix":"10.1016","volume":"228","author":[{"given":"Michal","family":"Felsinger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9088-5428","authenticated-orcid":false,"given":"Lubos","family":"Minar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vit","family":"Weinberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Rovny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Zlamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Bienertova-Vasku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejogrb.2018.06.036_bib0005","series-title":"SEER cancer statistics review, 1975\u20132012","year":"2015"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0010","series-title":"2012 v1.0, cancer incidence and mortality worldwide: IARC cancerBase No. 11 [internet]","author":"Ferlay","year":"2013"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ygyno.2015.08.004","article-title":"Final overall survival and safety analysis of OCEANS, a phase 3 trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent ovarian cancer","volume":"139","author":"Aghajanian","year":"2015","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0020","article-title":"Surgical cytoreduction for recurrent epithelial ovarian cancer","volume":"28","author":"Al Rawahi","year":"2013","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0025","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s11912-012-0260-x","article-title":"Surgery for relapsed ovarian cancer: when should it be offered?","volume":"14","author":"Harter","year":"2012","journal-title":"Curr Oncol Rep."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0030","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/jso.21652","article-title":"Role of secondary cytoreductive surgery in ovarian cancer relapse: who will benefit? A systematic analysis of 40 consecutive patients","volume":"102","author":"Sehouli","year":"2010","journal-title":"J Surg Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0035","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ygyno.2016.04.537","article-title":"Surgical management of recurrent ovarian cancer","volume":"142","author":"Suh","year":"2016","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0040","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ejso.2010.04.012","article-title":"Perioperative morbidity and outcome of secondary cytoreduction for recurrent epithelial ovarian cancer","volume":"36","author":"Woelber","year":"2010","journal-title":"Eur J Surg Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0045","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1097\/IGC.0000000000000327","article-title":"Prognostic significance of sugarbaker\u2019s peritoneal cancer index for the operability of ovarian carcinoma","volume":"25","author":"Lampe","year":"2015","journal-title":"Int J Gynecol Cancer."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0050","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/SLA.0b013e3181b13ca2","article-title":"The clavien-dindo classification of surgical complications: five-year experience","volume":"250","author":"Clavien","year":"2009","journal-title":"Ann Surg."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0055","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/cncr.21845","article-title":"Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma","volume":"106","author":"Chi","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0060","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1245\/s10434-006-9058-0","article-title":"Arbeitsgemeinschaft gynaekologische onkologie ovarian committee; AGO ovarian cancer study group. Surgery in recurrent ovarian cancer: the arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial","volume":"13","author":"Harter","year":"2006","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0065","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/IGC.0b013e31820aaafd","article-title":"Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the multicenter intergroup study DESKTOP II. A project of the AGO kommission OVAR, AGO study group, NOGGO, AGO-Austria, and MITO","volume":"21","author":"Harter","year":"2011","journal-title":"Int J Gynecol Cancer."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0070","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ygyno.2014.01.027","article-title":"Prognostic and predictive value of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) score in surgery for recurrent ovarian cancer","volume":"132","author":"Harter","year":"2014","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0075","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/IGC.0000000000000051","article-title":"Secondary complete cytoreduction in recurrent ovarian cancer: benefit of optimal patient selection using scoring system","volume":"24","author":"Laas","year":"2014","journal-title":"Int J Gynecol Cancer."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0080","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ygyno.2015.02.004","article-title":"External validation of two prediction models of complete secondary cytoreductive surgery in patients with recurrent epithelial ovarian cancer","volume":"137","author":"van de Laar","year":"2015","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0085","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1245\/s10434-011-1873-2","article-title":"A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection","volume":"19","author":"Tian","year":"2012","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0090","doi-asserted-by":"crossref","first-page":"4217","DOI":"10.1245\/s10434-015-4534-z","article-title":"A predictive score for secondary cytoreductive surgery in recurrent ovarian cancer (SeC-score): a single-centre, controlled study for preoperative patient selection","volume":"22","author":"Angioli","year":"2015","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0095","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10147-015-0910-8","article-title":"Proposal for selection criteria of secondary cytoreductive surgery in recurrent epithelial ovarian, tubal, and peritoneal cancers","volume":"21","author":"Minaguchi","year":"2016","journal-title":"Int J Clin Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0100","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1245\/s10434-014-4263-8","article-title":"Quality of life in platinum-sensitive recurrent ovarian cancer: chemotherapy versus surgery plus chemotherapy","volume":"22","author":"Plotti","year":"2015","journal-title":"Ann Surg Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0105","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/1757-2215-6-14","article-title":"CA-125-indicated asymptomatic relapse confers survival benefit to ovarian cancer patients who underwent secondary cytoreduction surgery","volume":"11","author":"Wang","year":"2013","journal-title":"J Ovarian Res"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0110","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.ygyno.2010.01.014","article-title":"Surveillance for the detection of recurrent ovarian cancer: survival impact or lead-time bias?","volume":"117","author":"Tanner","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0115","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ygyno.2011.01.014","article-title":"CA125 surveillance increases optimal resectability at secondary cytoreductive surgery for recurrent epithelial ovarian cancer","volume":"121","author":"Fleming","year":"2011","journal-title":"Gynecol Oncol."},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0120","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.ejogrb.2008.05.006","article-title":"Predictive value of PET\u2013CT imaging versus AGO-scoring in patients planned for cytoreductive surgery in recurrent ovarian cancer","volume":"140","author":"Lenhard","year":"2008","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1093\/annonc\/mdr470","article-title":"Follow-up with CA125 after primary therapy of advanced ovarian cancer: in favor of continuing to prescribe CA125 during follow-up","volume":"22","author":"Pignata","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0130","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s00259-014-2902-8","article-title":"[(18)F]FDG PET\/MRI vs. PET\/CT for whole-body staging in patients with recurrent malignancies of the female pelvis: initial results","volume":"42","author":"Beiderwellen","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.ejogrb.2018.06.036_bib0135","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4103\/wjnm.WJNM_31_17","article-title":"Systematic review on the accuracy of positron emission tomography\/computed tomography and positron emission tomography\/magnetic resonance imaging in the management of ovarian cancer: Is functional information really needed?","volume":"16","author":"Suppiah","year":"2017","journal-title":"World J Nucl Med."}],"container-title":["European Journal of Obstetrics & Gynecology and Reproductive Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518303208?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301211518303208?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T05:43:32Z","timestamp":1759556612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301211518303208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":27,"alternative-id":["S0301211518303208"],"URL":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.06.036","relation":{},"ISSN":["0301-2115"],"issn-type":[{"value":"0301-2115","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Secondary cytoreductive surgery - viable treatment option in the management of platinum-sensitive recurrent ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Obstetrics & Gynecology and Reproductive Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejogrb.2018.06.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}